CLEC9A
(C-Type Lectin Domain Family 9, Member A (CLEC9A))
Type de proteíne
Recombinant
Attributs du protein
AA 57-241
Origine
Humain
Source
HEK-293 Cells
Purification/Conjugué
Cette CLEC9A protéine est marqué à la Fc Tag.
Fonction
Human CLEC9A Protein
Séquence
Lys57-Val241
Attributs du produit
Recombinant Human CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Val241.
Pureté
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Stérilité
0.22 μm filtered
niveau d'endotoxine
Less than 1EU per μg by the LAL method.
Biological Activity Comment
Immobilized Human CLEC9A, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC9A Antibody, hFc Tag with the EC50 of 4.4ng/ml determined by ELISA. See testing image for detail.
CLEC9A
Origine: Rat
Hôte: Levure
Recombinant
> 90 %
ELISA
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
Buffer
Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
Stock
-20 °C,-80 °C
Stockage commentaire
-20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Date de péremption
12 months
Antigène
CLEC9A
(C-Type Lectin Domain Family 9, Member A (CLEC9A))
9830005G06Rik Protein, DNGR-1 Protein, DNGR1 Protein, UNQ9341 Protein, RGD1562513 Protein, C-type lectin domain family 9, member a Protein, C-type lectin domain containing 9A Protein, C-type lectin domain family 9, member A Protein, Clec9a Protein, CLEC9A Protein
Sujet
CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
Poids moléculaire
48.5 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.